Revolution Medicines, Inc. filed a Form 8-K on September 1, 2026, disclosing that on August 27, 2026, the company entered into four lease agreements for approximately 672,000 rentable square feet across four buildings in Redwood City, California, intended to serve as its new headquarters.

Key Highlights

  • Four buildings leased: The premises are located at 1600, 1700, 1800, and 1900 Seaport Boulevard in Redwood City, California, totaling approximately 672,000 rentable square feet.
  • Staggered commencement: Lease commencement dates begin September 26, 2027 and extend through September 1, 2028, with initial terms each ending in September 2042.
  • Monthly base rent: At full commencement of all leases, aggregate scheduled monthly base rent will begin at approximately $2.7 million, increasing by approximately 3% annually.
  • Rent abatement: The leases include rent-abatement periods extending through January 2030, representing an aggregate base rent abatement of approximately $23.1 million.
  • Tenant improvement allowances: Landlords agreed to provide approximately $115.9 million in aggregate tenant improvement allowances, with an option for up to approximately $40.3 million in additional allowances.
  • Related-party note: Farallon Capital Management, L.L.C. reported beneficial ownership of approximately 6.4% of the company's outstanding common stock as of June 30, 2026, and investment funds managed by Farallon indirectly own a majority interest in the landlords.
  • Termination conditions: If the Phase II Closing does not occur by December 31, 2026, the company may terminate each lease; each lease automatically terminates if the Phase II Closing has not occurred by April 29, 2027, absent a mutually agreed extension.

Revolution Medicines Commits to Major Redwood City Campus Expansion

According to the filing, Revolution Medicines (NASDAQ:RVMD) entered into four separate lease agreements on August 27, 2026, with four affiliated landlords, each a subsidiary of Pacific Shores Phase II Associates, LLC. The leases cover the entirety of four buildings at 1600, 1700, 1800, and 1900 Seaport Boulevard in Redwood City, California, aggregating approximately 672,000 rentable square feet. The company disclosed that it intends to use the premises as its new headquarters.

The filing states that the leases carry staggered commencement dates beginning September 26, 2027 through September 1, 2028, with initial terms each ending in September 2042. The company also holds options to extend each lease for up to three additional five-year periods, with base rent during any extension period to be determined based on fair market rent. At full commencement, aggregate scheduled monthly base rent will begin at approximately $2.7 million, rising by approximately 3% annually. The company disclosed rent-abatement periods extending through January 2030, representing approximately $23.1 million in aggregate base rent abatement.

The filing also discloses that the effectiveness of the leases is conditioned on the landlords' acquisition of the properties, referred to as the "Phase II Closing." If that closing occurs after November 24, 2026 but on or before December 31, 2026, base rent would be reduced by $0.02 per rentable square foot per month; if after December 31, 2026, the reduction would be $0.10 per rentable square foot per month. The filing notes that Farallon Capital Management, L.L.C., which reported beneficial ownership of approximately 6.4% of the company's outstanding common stock as of June 30, 2026, indirectly owns a majority interest in the landlords through investment funds it manages. The company stated the filing also constitutes disclosure under Item 2.03 regarding the creation of a direct financial obligation. The filing contains forward-looking statements, which the company cautions are subject to risks and uncertainties.

What Was Disclosed

Revolution Medicines disclosed entry into four leases totaling approximately 672,000 square feet for a new headquarters in Redwood City, California, with monthly base rent beginning at approximately $2.7 million, approximately $115.9 million in tenant improvement allowances, and lease effectiveness contingent on the landlords completing a property acquisition.